Search

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.ahj.2007.04.059 Byline: David E. Lanfear (a), Philip G. Jones (b), Sharon Marsh (c), Sharon Cresci (d), John A. Spertus (b)(e), Howard L. McLeod (f) Abstract: GJA4 1019 C > T, MMP3 -1171delA, and SERPINE1 -668delG genotypes have been associated with the risk of incident myocardial infarction. We tested the hypothesis that these genotypes would predict long-term mortality after an acute coronary syndrome (ACS). Author Affiliation: (a) Henry Ford Heart and Vascular Institute and Wayne State University, Detroit, MI (b) Mid America Heart Institute, Kansas City, MO (c) Department of Medicine, Washington University School of Medicine, St Louis, MO (d) Cardiovascular Diseases Division, Department of Medicine, Washington University School of Medicine, St Louis, MO (e) University of Missouri-Kansas City, Kansas City, MO (f) Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill, NC Article History: Received 1 December 2006; Accepted 29 April 2007 Article Note: (footnote) This work was supported in part by R01 HS11282-01 from the Agency for Healthcare Research and Quality, the NIH Pharmacogenetics research network (U01 GM63340), a Heart Failure Society of America Research Fellowship grant, and NIH SCCOR (P50 HL077113)., Dr Howard L. McLeod is a member of an advisory board for the US Food and Drug Administration.

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.ahj.2005.05.026 Byline: John A. Spertus (a)(b), Eric Peterson (d), John S. Rumsfeld (e), Philip G. Jones (a)(b), Carole Decker (a)(b), Harlan Krumholz (c) Abstract: More information on the longitudinal care and outcomes of patients after myocardial infarction (MI) is needed to further improve the quality of MI care. The PREMIER study was designed to meet this need. Author Affiliation: (a) Mid America Heart Institute, Kansas City, MO (b) University of Missouri-Kansas City, Kansas City, MO (c) Yale University, New Haven, CT (d) Duke University Medical Center, Durham, NC (e) Denver VA Medical Center/University of Colorado Health Sciences Center, Denver, CO Article History: Received 4 March 2005; Accepted 2 May 2005 Article Note: (footnote) This study was principally supported by CV Therapeutics, Inc, Palo Alto, CA, and R-01 HS11282-01 from the Agency for Healthcare Research and Quality, Rockville, MD. This study was also supported by a Veterans Affairs Health Services Research Advanced Research Career Development Award (ARCD-98-341-2) (Dr Rumsfeld), Washington, DC.